Supernus Pharmaceuticals Quarterly Balance Sheet
NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Supernus Pharmaceuticals financial position
As of Jun 30, 2026, Supernus Pharmaceuticals reported total assets of $1.43 billion, up 3.3% from a year earlier against total liabilities of $396.9 million. Shareholders' equity stood at $1.03 billion, or 72.2% of assets. The company held $180.0 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 2.08, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Supernus Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 179.95M | 184.87M | 128.45M | 151.37M | 144.71M | 115.85M | 69.33M | 31.67M | 52.09M | 63.40M | 75.05M | 94.98M |
| Receivables | 211.66M | 182.18M | 187.80M | 171.25M | 140.83M | 145.64M | 142.08M | 145.41M | 152.49M | 147.73M | 144.16M | 141.76M |
| Inventory | 107.03M | 110.77M | 112.48M | 107.10M | 44.02M | 49.42M | 54.29M | 63.98M | 68.16M | 75.08M | 77.41M | 83.48M |
| Total Current Assets | 723.50M | 731.58M | 644.18M | 593.89M | 738.87M | 687.58M | 686.07M | 640.00M | 591.00M | 544.32M | 493.11M | 449.36M |
| Property, Plant & Equipment | 10.20M | 10.04M | 10.53M | 10.63M | 11.07M | 11.34M | 11.54M | 11.88M | 12.27M | 12.97M | 13.53M | 13.69M |
| Goodwill | 119.43M | 120.67M | 124.88M | 119.08M | 117.02M | 117.02M | 117.02M | 117.02M | 117.02M | 117.02M | 117.02M | 117.02M |
| Intangible Assets | 469.46M | 549.71M | 569.46M | 623.48M | 481.31M | 502.13M | 521.91M | 540.16M | 559.64M | 579.75M | 599.89M | 641.15M |
| Total Assets | 1.43B | 1.50B | 1.45B | 1.42B | 1.38B | 1.35B | 1.37B | 1.34B | 1.32B | 1.30B | 1.28B | 1.29B |
| Accounts Payable | 5.59M | 10.17M | 2.68M | 8.18M | 8.21M | 7.07M | 4.59M | 6.39M | 4.63M | 14.40M | 1.96M | 3.39M |
| Total Current Liabilities | 347.38M | 373.93M | 338.17M | 330.63M | 286.36M | 281.77M | 292.40M | 291.51M | 308.66M | 314.55M | 290.20M | 287.53M |
| Total Liabilities | 396.88M | 423.92M | 390.93M | 370.09M | 318.50M | 316.58M | 332.34M | 335.55M | 358.38M | 374.92M | 356.16M | 372.97M |
| Shareholders' Equity | 1.03B | 1.08B | 1.06B | 1.05B | 1.06B | 1.03B | 1.04B | 1.01B | 957.45M | 929.17M | 921.52M | 912.19M |
| Retained Earnings | 457.21M | 515.58M | 517.88M | 521.98M | 567.10M | 544.60M | 556.43M | 541.10M | 502.60M | 482.69M | 482.56M | 481.39M |
| Net Cash (Debt) | 179.95M | 184.87M | 128.45M | 151.37M | 144.71M | 115.85M | 69.33M | 31.67M | 52.09M | 63.40M | 75.05M | 94.98M |
| Shares Outstanding | 58.16M | 58.04M | 57.46M | 57.12M | 56.12M | 55.99M | 55.74M | 55.22M | 55.05M | 54.72M | 54.72M | 54.25M |
This table shows 12 quarterly periods of Supernus Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow SUPN's reporting calendar. What is a balance sheet?